Sources checked November 20, 2026.
What does a medical weight loss program include?
The 2013 obesity guideline from the American Heart Association, the American College of Cardiology and The Obesity Society describes a "comprehensive lifestyle intervention" with three parts: a moderately reduced-calorie diet, a program of increased physical activity, and behavioral strategies to help people keep to both.[1]
The same guideline advises a program lasting at least six months and recommends on-site, "high-intensity (ie, ≥14 sessions in 6 mo)" sessions, given individually or in groups by a trained interventionist.[1]
For the diet part, the guideline lists calorie targets of usually 1,200 to 1,500 kcal a day for women and 1,500 to 1,800 kcal a day for men, or an estimated individual energy need minus 500 or 750 kcal a day.[1] Our BMR calculator and TDEE calculator do that arithmetic from height, weight, age and activity level.
The US Preventive Services Task Force gives a grade B recommendation that clinicians offer or refer adults with a BMI of 30 or higher to intensive, multicomponent behavioral interventions. Its September 18, 2018 statement describes programs that mostly ran one to two years, with at least 12 sessions in the first year in most of them.[4]
The 2025 algorithm from the American Association of Clinical Endocrinology (AACE) frames obesity as adiposity-based chronic disease. Its sections run from screening and diagnosis through an individualized treatment plan with goals and follow-up, behavioral and lifestyle therapy, medicine choices, and the FDA-approved obesity medicines. It puts weight on clinical goals beyond BMI alone.[5]
Surgery sits at the far end of the same care path. The 2013 guideline advises referral to "an experienced bariatric surgeon" for adults who meet the surgical BMI thresholds and have not reached their health goals with behavioral treatment, with or without medicine.[1]
Who qualifies for medical weight loss?
Different parts of medical weight loss use different BMI cutoffs. The table shows each threshold as the source states it.
Overweight and obesity cutpoints: Threshold as published: Overweight: BMI 25.0 to 29.9. Obesity: BMI 30 or higher.; Source: AHA/ACC/TOS 2013 guideline[1]
Intensive behavioral program: Threshold as published: BMI 30 or higher; Source: USPSTF 2018 (grade B)[4]
FDA-approved long-term obesity medicine: Threshold as published: BMI 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol; Source: FDA, Zepbound approval announcement[6]; AGA 2022 guideline[2]
Phentermine (short-term use): Threshold as published: Initial BMI 30 or higher, or 27 or higher with other risk factors; Source: Phentermine prescribing information[7]
Metabolic and bariatric surgery: Threshold as published: Recommended at BMI 35 or higher regardless of other conditions; to be considered at BMI 30 to 34.9 with metabolic disease; lower thresholds for Asian populations; Source: ASMBS and IFSO 2022[3]
Newer drug labels state the indication in words, as "adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition", rather than printing the BMI numbers in the indication itself.[8][9] The trials behind them used the numeric cutoffs: the main adult Saxenda study, for example, enrolled people with a BMI of 30 or higher, or 27 to 29.9 with at least one weight-related condition.[10]
The 2022 surgical statement from the American Society for Metabolic and Bariatric Surgery and the International Federation for the Surgery of Obesity and Metabolic Disorders replaced the 1991 NIH thresholds.[3] The 2013 guideline had used a BMI of 40 or higher, or 35 or higher with obesity-related conditions.[1]
What happens at a first medical weight loss visit?
The 2013 guideline lists what a risk assessment includes for an adult with overweight or obesity: a history, a physical examination, and clinical and lab measures "including BP, fasting blood glucose, and fasting lipid panel."[1]
Height, weight and BMI. The guideline recommends measuring these at annual visits or more often.[1]
Waist circumference. Recommended for people with a BMI of 25 to 34.9. The guideline uses more than 88 cm (35 in) for women and more than 102 cm (40 in) for men as markers of higher cardiometabolic risk.[1]
Blood pressure, fasting glucose and fasting lipids. These are the clinical and lab measures the guideline names.[1]
Weight-related conditions. The AACE algorithm has separate steps for the body-size measures and for the clinical part of the diagnosis, meaning the complications a person already has.[5]
Some medicines add their own tests. The Qsymia label calls for a negative pregnancy test before starting and monthly during treatment in people who can become pregnant, and a blood chemistry profile with bicarbonate, creatinine and potassium before and during treatment.[11] The Wegovy label asks prescribers to monitor blood glucose before starting in patients with diabetes.[12]
A visit that ends with a plan should leave a record of goals and a follow-up schedule. The AACE algorithm includes an individualized treatment plan, therapeutic goals and follow-up, and a separate step for judging response to therapy.[5]
Which weight loss medications are FDA-approved?
As of November 20, 2026, these are the FDA-approved prescription medicines labeled for chronic weight management. Each label pairs the medicine with a reduced-calorie diet and increased physical activity.[12][8][9][10][11][13][14]
Wegovy injection (semaglutide): How it is taken: Once-weekly injection; FDA approval: June 4, 2021[15]; Weight indication on the label: Adults with obesity; adults with overweight and at least one weight-related condition; ages 12 and older with obesity[12]; Other labeled uses or label notes: Cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight (March 8, 2024)[16]; noncirrhotic MASH with moderate to advanced liver fibrosis in adults, under accelerated approval (August 2025)[12][15]
Wegovy tablets (semaglutide): How it is taken: Once-daily tablet; FDA approval: December 22, 2025[17]; Weight indication on the label: Adults with obesity, or with overweight and at least one weight-related condition[12]; Other labeled uses or label notes: Cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight[12]
Zepbound (tirzepatide): How it is taken: Once-weekly injection; FDA approval: November 8, 2023[6]; Weight indication on the label: Adults with obesity, or with overweight and at least one weight-related condition[8]; Other labeled uses or label notes: Moderate to severe obstructive sleep apnea in adults with obesity (December 20, 2024)[18]
Foundayo (orforglipron): How it is taken: Once-daily tablet; FDA approval: April 1, 2026[19]; Weight indication on the label: Adults with obesity, or with overweight and at least one weight-related condition[9]; Other labeled uses or label notes: Label says use with another GLP-1 receptor agonist "is not recommended"[9]
Saxenda (liraglutide): How it is taken: Once-daily injection; FDA approval: December 23, 2014[20]; Weight indication on the label: Adults with overweight and at least one weight-related condition; adults and ages 12 and older with obesity and body weight above 60 kg[10]
Qsymia (phentermine and topiramate extended-release): How it is taken: Once-daily capsule, taken in the morning; FDA approval: July 17, 2012[21]; Weight indication on the label: Adults and ages 12 and older with obesity; adults with overweight and at least one weight-related condition[11]; Other labeled uses or label notes: Phentermine is a Schedule IV controlled substance; the label carries a Risk Evaluation and Mitigation Strategy (REMS)[11]
Contrave (naltrexone and bupropion extended-release): How it is taken: Tablets, built up to two tablets twice a day by week 4; FDA approval: September 10, 2014[22]; Weight indication on the label: Adults with obesity, or with overweight and at least one weight-related condition[13]; Other labeled uses or label notes: Label: effect on cardiovascular illness and death "has not been established"[13]
Phentermine (generic and brand tablets or capsules): How it is taken: By mouth; FDA approval: Initial US approval 1959[7]; Weight indication on the label: Short-term ("a few weeks") add-on to diet, exercise and behavior change, at an initial BMI of 30 or higher, or 27 or higher with other risk factors[7]; Other labeled uses or label notes: Schedule IV controlled substance[7]
Xenical (orlistat 120 mg): How it is taken: Capsule three times a day with meals that contain fat; FDA approval: April 23, 1999[14]; Weight indication on the label: Adults and ages 12 and older with obesity; adults with overweight and at least one weight-related condition[14]; Other labeled uses or label notes: A lower-strength orlistat product, Alli, was approved for sale without a prescription on February 7, 2007[23]
Semaglutide and tirzepatide each have their own page: semaglutide and tirzepatide. Our guide to GLP-1 weight loss covers the drug class.
Is Foundayo (orforglipron) FDA approved?
Yes. The FDA approved Foundayo on April 1, 2026, as a once-daily tablet for chronic weight management in adults with obesity, or with overweight and at least one weight-related condition. The agency cited two randomized, double-blind, placebo-controlled trials and called it the first new molecular entity approved under its National Priority Voucher program.[19] The label's first US approval year is 2026.[9]
Compounded and investigational versions
Compounded semaglutide and tirzepatide are not the products in the table. The FDA states that "compounded drugs are not FDA approved" and that it does not review them for safety, effectiveness or quality before they are sold.[24] The same FDA page says salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients from those in the approved drugs, and it warns about GLP-1 products labeled "for research purposes" or "not for human consumption" that have been sold to consumers.[24] Our pages on compounded semaglutide and compounded tirzepatide cover this in detail.
Retatrutide is investigational. Lilly's September 29, 2026 announcement says it plans to submit a Biologics License Application to the FDA in the first quarter of 2027.[25]
GLP-1 medicines and longevity: what SELECT measured
SELECT enrolled 17,604 people aged 45 or older with preexisting cardiovascular disease, a BMI of 27 or higher and no history of diabetes, and randomly assigned them to weekly semaglutide 2.4 mg or placebo.[26]
The primary outcome was a first event of cardiovascular death, nonfatal heart attack or nonfatal stroke. Over a mean follow-up of 39.8 months, it occurred in 569 of 8,803 people (6.5%) in the semaglutide group and 701 of 8,801 (8.0%) in the placebo group, a hazard ratio of 0.80 (95% confidence interval 0.72 to 0.90).[26]
Adverse events that led to permanently stopping the trial drug occurred in 16.6% of the semaglutide group and 8.2% of the placebo group.[26]
On March 8, 2024, the FDA approved Wegovy injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight.[16] The current label gives Wegovy tablets the same cardiovascular indication.[12]
SELECT measured time to a first major cardiovascular event, not lifespan.[26] None of the labeled indications in the table above refers to aging or length of life.
How much does medical weight loss cost?
A program's cost has two parts: the clinic's own fees for visits, labs and coaching, which each clinic sets, and the medicine. Manufacturer self-pay prices, as published on November 20, 2026:
Wegovy tablets: Published self-pay price: $149 a month (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg); Conditions stated by the manufacturer: One month is a bottle of 30 tablets; eligibility and restrictions apply[27]
Wegovy injection: Published self-pay price: $349 a month (0.25 mg to 2.4 mg); $399 (Wegovy HD 7.2 mg); Conditions stated by the manufacturer: New patients pay $199 a month for 0.25 mg and 0.5 mg for two monthly fills through December 31, 2026[27]
Zepbound vial or KwikPen: Published self-pay price: From $299 a month (2.5 mg), $399 (5 mg), $449 (7.5 mg to 15 mg); Conditions stated by the manufacturer: The $449 price applies when refilled within 45 days; otherwise $499 (7.5 mg) or $699 (10 mg to 15 mg)[28]
Foundayo: Published self-pay price: From $149 a month for the lowest dose; Conditions stated by the manufacturer: Lilly's April 1, 2026 launch announcement[29]
Both manufacturers say these offers can change. Novo Nordisk "reserves the right to modify or cancel this program at any time."[27] Ask a clinic for its own fees in writing, separately from the medicine price.
Does Medicare cover weight loss medication?
Not under the standard Part D benefit. CMS's Part D manual lists "agents when used for anorexia, weight loss, or weight gain (even if used for a noncosmetic purpose (i.e., morbid obesity))" among the drugs excluded from Part D.[30] In April 2025, CMS said it was not finalizing a proposal to cover anti-obesity medicines under Part D.[31]
Since July 1, 2026, a separate CMS demonstration called the Medicare GLP-1 Bridge has given eligible Part D enrollees certain GLP-1 medicines for a $50 copay, outside the Part D benefit. It runs through December 31, 2027.[32][33] The covered products are Foundayo, Wegovy (all formulations) and the Zepbound KwikPen; Zepbound single-dose vials and pens are not included.[32]
The Bridge requires the medicine to be prescribed to reduce and maintain body weight with lifestyle changes, for an enrollee aged 18 or older who, at the start of GLP-1 therapy, had one of these:[32]
a BMI of 35 or higher;
a BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled high blood pressure, or chronic kidney disease stage 3a or higher;
a BMI of 27 or higher with prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.
The pharmacy requests prior authorization, decisions come within 72 hours, and CMS states "There is no appeals process under Medicare GLP-1 Bridge."[32] No part of the $50 copay counts toward the enrollee's true out-of-pocket costs.[34]
People with type 2 diabetes, moderate to severe obstructive sleep apnea, or noncirrhotic MASH are routed to their regular Part D plan instead, as are prescriptions written to reduce the risk of major cardiovascular events.[32] CMS has delayed the Part D portion of its longer-term BALANCE model for 2027.[33]
How do I choose a medical weight loss clinic?
These checks come from public licensing records and from what the guidelines and labels above say a program should cover.
Check the prescriber's license. DocInfo, run by the Federation of State Medical Boards, draws on a national database of medical licensure and disciplinary actions reported by state medical boards.[35] Your state's medical, nursing or physician assistant board holds the full record for the person who will prescribe.
Ask who prescribes and who follows up. Ask for the name and license type of the clinician who writes the prescription, and who you see at follow-up visits.
Ask about obesity medicine certification. The American Board of Obesity Medicine keeps a public directory of its diplomates with certification dates; certification lasts 10 years.[36]
Ask which product you would receive. An FDA-approved brand from the table above and a compounded product are different things under FDA rules.[24]
Ask what gets documented. A program working from the guidelines records BMI, waist circumference where it applies, blood pressure, fasting glucose and lipids, existing weight-related conditions, a written plan with goals, and a follow-up schedule.[1][5]
Ask about the full care path. That means the lifestyle and behavioral program, not only a prescription, and whether the clinic refers to an experienced bariatric surgeon when someone meets surgical thresholds.[1][3]
Get the price in writing. Ask for visit, lab and program fees separately from the medicine price.
Medical weight loss clinics in our directory
Regenerated.com lists 972 clinics whose own websites describe a medical weight loss program, checked November 20, 2026. Browse medical weight loss clinics by state and city. A listing reflects what a clinic says about itself; it is not an endorsement, and it does not confirm which medicines a clinic prescribes.